Malbari F, Quinlan A, Hanson D, Levy A and Atlas M
Background: Temozolomide (TMZ) is effective in CNS embryonal tumors and well tolerated. The aim of this study is to evaluate tolerability of temozolomide in conjunction with craniospinal irradiation (CSI) in this patient group.
Methods: Retrospective chart review conducted of patients from 1/1/02-10/31/12. Nine charts reviewed; Information obtained included: tumor type, treatment regimen, side effects and management.
Results: Eight of nine patients completed CSI with minimal side effects. Two experienced delay in treatment secondary to myelosuppression, one requiring premature discontinuation of temozolomide. All patients tolerated maintenance chemotherapy with minor adjustments.
Conclusions: CSI with temozolomide was well tolerated. Further investigation is warranted.
